Expression of the cellular prion protein (PrPC) from the PRNP gene is crucial for the development of a group of fatal neurodegenerative disorders called prion diseases. During prion infection a misfolded protein homologue of PrPC, PrPSc causes further misfolding on interaction with native PrPC molecules. PrPSc is highly resistant to proteinase K and aggregation of this protein is considered a hallmark of infection. Sheep are considered a model of natural infection and susceptibility to scrapie in sheep is defined by polymorphisms in the PRNP gene. It is still not fully understood how these polymorphisms regulate the conversion process or which other co-factors are involved. One such factor may be the truncation of PrPC via proteolytic processing in the form of two main cleavage events, known as α- and β-cleavage. In sheep α-cleavage cuts at amino acid 115, creating two truncated proteins C1 and N1 and represents the main cleavage event in healthy brain. β-Cleavage creates a longer C-terminal fragment, C2 and corresponding N-terminal fragment N2, cutting around amino acid 92 in sheep. Truncated forms of PrPC have been shown to represent around 50 % of total residual PrP in brain and may be an important determinant of disease through both decreasing the amount of full length PrPC available for conversion and through functions associated with the truncated fragments. The research presented has shown that increased production of an α-cleavage fragment C1 in brain is associated with TSE resistant genotype ARR/ARR, while the presence of C2 fragment is affiliated with scrapie susceptible PRNP genotypes in brain. There was no difference in the levels of full length PrPC in these genotypes suggesting that PrP expression does not directly correlate to susceptibility in this model. To assess if PrPC fragments could affect the conversion during disease in-vitro fibrillisation assays were performed using novel truncated recombinant proteins. These truncated proteins, although not thought to convert to PK resistant PrPSc during disease, can form amyloid fibrils. However, these fibrils appear to be less neurotoxic when compared to fibrils produced by full length PrPC. Only the truncated fragments derived from the ARR allele inhibit in-vitro fibrillisation of other allelic PrPC variants. Furthermore, treatment of infected cells in culture with recombinant C1ARR led to a decrease in the formation of disease associated PrPSc. In conclusion, genetic variations in levels of PrP truncated fragments may add to the complexity of genetic determinants of prion disease. In parallel with polymorphism-dependant conversion abilities, varying α-cleavage of ovine PrPC may help to explain genetic resistance in sheep. The inhibitory effects of C1, illustrated in-vitro may represent a therapeutic avenue in the treatment of prion disease.

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

C1-esterase inhibitor (C1-inh) can inhibitor the first complement protein as C1s and C1r activity to reach adjust classical pathway, avoid excessive activation of the complement system to cause disease. C1-inhibitor protein composed of 478 amino acids with two domains: C terminal domain (serpin domain) and N terminal domain. The early focus has been to angioedema associated with cancer found so far. So the purpose of the study was to investigate whether the C1-inh cause for the breast cancer cell proliferation and migration. We use recombinant gene transform Escherichia coli strain BL21(DE3) and expression. Recombinant protein was purified using affinity column. Influence of proliferation and migration on breast cancer cells were tested by purified recombinant C1-inh. In breast cancer cell proliferation results showed, C1-inh significant proliferation of breast cancer, and when the higher concentration, the longer the incubation time, the remarkable effect of promoting proliferation is even more obvious. The results in breast cancer cell migration is also significant in the C1-inh to promote breast cancer cell migration, and when the higher concentration of the longer incubation time, the significant increased migration is more effective. Therefore, this study does note C1-inh to promote breast cancer cell proliferation and migration.

No description available.

No description available.

No description available.

No description available.

A ativação dos sistemas complemento e de contato resulta na formação de peptídeos vasoativos tais como a bradicinina e anafilatoxinas. O inibidor de C1-esterase (C1-INH) é o principal regulador desses dois sistemas e a deficiência desta proteína resulta no Angioedema Hereditário (AEH). Trata-se de uma doença rara, de herança autossômica dominante, caracterizada pela deficiência de C1-INH, a qual ocorre devido a mutações no seu gene estrutural, levando a episódios graves de edema em tecido subcutâneo, gastrointestinal e respiratório, potencialmente fatais. Existem dois fenótipos variantes: AEH do tipo I, com reduzidos níveis antigênicos de C1-INH no plasma e AEH tipo II com níveis reduzidos ou normais de C1-INH e atividade disfuncional. Várias mutações já foram descritas no gene de inibidor de C1 esterase (SERPING1), porém, não há estudos que avaliem a relevância desta doença e as mutações gênicas em nosso meio. O objetivo do presente estudo foi avaliar as alterações moleculares em pacientes com AEH, correlacionando-as com as manifestações clínico-laboratoriais. Amostras de plasma, soro e DNA de quinze pacientes de uma mesma família foram coletadas. O ensaio hemolítico CH50 para avaliação da integridade da via clássica do sistema complemento e avaliação quantitativa de C4 e C1-INH por nefelometria foram os ensaios realizados para confirmação do diagnóstico da doença. A atividade funcional da proteína foi avaliada através de ensaio colorimétrico e a relação existente entre possíveis mutações na proteína e o fenótipo da doença foi avaliada por meio de reação de polimerase em cadeia (PCR) e seqüenciamento do DNA genômico. A atividade hemolítica de complemento total e a dosagem de C3 foram normais nos pacientes e controles analisados, os níveis da atividade antigênica de C1-INH e C4 mostraram-se diminuídos na maioria dos avaliados (13/15). A avaliação funcional detectou baixa atividade (<50%) do valor normal (70% - 130%) em todos os pacientes analisados. A distribuição das mutações entre os 8 éxons relativos ao gene de C1- INH concentraram-se nos éxons 4 (g.4706-88A>G) , 7 (g.14145+20A>G) e 8 (Val480Met). Duas dessas mutações nunca foram descritas ainda, o que contribui para a compreensão da função das serpinas e também ajuda a definir mais completamente o papel biológico do inibidor de C1 / Activation of complement and contact systems results in the formation of vasoactive peptides such as bradykinin and anafilatoxinas. The C1 esterase inhibitor (C1-INH) is the main regulator of these two systems and the deficiency of this protein results in hereditary angioedema (HAE). It is a rare disease of autosomal dominant inheritance, characterized by deficiency of C1-INH, which is due to mutations in its structural gene, leading with severe episodes of edema in subcutaneous tissue, gastrointestinal and respiratory tract, potentially fatal. There are two phenotypic variants: HAE type I, with reduced plasma antigen levels and HAE type II with normal or low levels of C1-INH and dysfunctional activity. Several mutations have been described in the gene of the C1 esterase inhibitor (SERPING1), however, no studies to assess the relevance of this disease and the gene mutations in our population. The purpose of this study was to evaluate the molecular changes in patients with HAE, correlating it with clinical and laboratory manifestations. Samples of plasma, serum and DNA from fifteen patients from the same family were collected. CH50 hemolytic assay for assessing the integrity of the classical pathway of the complement system and quantitative evaluation of C1-INH and C4 by nephelometry tests were performed to confirm the diagnosis of disease. The functional activity of the protein was assessed by colorimetric assay and the possible relationship between mutations in the protein and the phenotype of the disease was assessed by polymerase chain reaction (PCR) and sequencing of genomic DNA. Hemolytic activity of complement and the total dosage of C3 were normal in patients and controls. Levels of antigenic activity of C1-INH and C4 were shown to be less valued in most (13/15). Functional evaluation found low activity (<50%) of normal (70% - 130%) in all patients examined. The distribution of mutations among the 8 exons of the gene for C1-INH concentrate in the exons 4 (g.4706-88A> G) and 7 (g.14145 +20 A> G) and 8 (Val480Met). Two of these mutations have not been described yet, which contributes to understanding the function of serpins and also helps to define more fully the biological role of the C1 inhibitor

A redução na pressão parcial de O2 é detectada pelos quimiorreceptores periféricos que sinalizam ao sistema nervoso central para que haja uma correção na homeostasia. Estudos neuroanatômicos mostram que neurônios C1 enviam projeções para núcleo paraventricular do hipotálamo (PVH), mas, pouco descrevem a participação desta via em uma situação de hipóxia. Ademais, o envolvimento de mecanismos neuroimunes no controle neural cardiorrespiratório durante a hipóxia não está esclarecido. Neste estudo mostramos que neurônios catecolaminérgicos do BVLr/C1 ativados por hipóxia se projetam para o PVH, e que a integridade destes neurônios é essencial para que neurônios do PVH sejam ativados por hipóxia. Além disso, o tratamento com minociclina alterou a expressão de mediadores inflamatórios no BVLr e PVH, a expressão de Fos e as repostas respiratória e autônoma desencadeadas pela hipóxia. Estes resultados conferem uma importante caracterização sobre a distribuição dos neurônios catecolaminérgicos do BVLr/C1 que são ativados por hipóxia e se projetam para o PVH. Além de mostrar que a hipóxia pode desencadear mecanismos neuroimunes que possivelmente envolvem a participação da microglia e também recrutam a via neural C1- PVH. / The reduction in the O2 partial pressure is detected by the peripheral chemoreceptors that send information to central nervous system to correct the homeostasis. Neuroanatomical studies show that C1 neurons send projections to the paraventricular hypothalamic nucleus (PVH), but rather describe the involvement of this pathway in a hypoxic situation. Furthermore, the potential involvement of neuroimmune mechanisms in cardiorespiratory neural control during hypoxia is unclear. In this study we show that catecholaminergic neurons localized in rostral ventrolateral medulla (RVLM) / C1 cells activated by hypoxia send projections to the PVH, and the integrity of these neurons is essential for PVH neurons be activated by hypoxia. Moreover, treatment with Minocycline changed the expression of inflammatory mediators in RVLM and PVH, the expression of Fos in these nucleus, and respiratory and autonomic responses elicited by hypoxia. These findings provide an important characterization of the distribution of catecholaminergic RVLM / C1 neurons that are activated by hypoxia and project to the PVH. In addition to showing that hypoxia can trigger neuroimmune mechanisms that possibly involve the microglia activity and also recruit the C1/PVH neural pathway.

Le terme folate (vitamine B9) désigne une famille de molécules ayant une structure de base composée de 3 parties : un noyau pterine, un acide para-aminobenzoïque (pABA) et une chaine de glutamates. Le rôle de ces cofacteurs est de transporter des groupements monocarbonés. Ils interviennent dans de nombreuses réactions comme la synthèse des bases nucléiques, la synthèse de méthionine et la synthèse et le turnover de la S-adenosylmethionine,. Le folate est synthétisé chez les plantes et un grand nombre de micro-organismes dont les parasites du phylum des apicomplexes, tels que Plasmodium falciparum, et Toxoplasma gondii. Les enzymes impliquées dans cette voie de biosynthèse étant absentes chez l'homme, elles représentent des cibles herbicides, antibiotiques et antiparasitaires potentielles. Les inhibiteurs de la voie de biosynthèse du folate (tels que les sulfamides, analogues du pABA et inhibiteurs de la dihydroptéroate synthase, ou les inhibiteurs de la dihydrofolate réductase), sont souvent utilisés comme antibiotiques et antiparasitaires. Un problème majeur dans le traitement de ces maladies infectieuses est la résistance développée contre ces molécules, ce qui nécessite la recherche permanente de nouveaux médicaments. Le pABA est synthétisé en plusieurs étapes qui sont autant de cibles intéressantes pour développer de nouveaux inhibiteurs. Tout d'abord l'aminodeoxychorismate (ADC) synthase transforme le chorismate en ADC, puis dans une seconde étape, l'ADC est transformé en pABA par une ADC lyase. Chez les plantes supérieures et les parasites apicomplexes l'ADC synthase est une enzyme bifonctionnelle composée de deux grands domaines, un domaine glutamine amidotranferase (GAT) qui permet de produire le NH3 nécessaire à l'amination du chorismate, et un domaine ADC synthase (ADCS). Nous avons pu déterminer les paramètres cinétiques de la GAT-ADCS d'Arabidopsis. Nous avons constaté que ces deux domaines fonctionnent indépendamment, c'est-à-dire soit en présence de glutamine seule pour le domaine GAT (pas de chorismate), soit en présence de chorismate et de NH3 pour le domaine ADCS (pas de glutamine). Toutefois, le fonctionnement en tandem des deux domaines (tous les substrats sont présents) améliore les propriétés cinétiques (kcat) de chacun d'eux. Nos résultats montrent aussi que le NH3 produit par le domaine GAT et nécessaire à la synthèse de l'ADC n'est pas relargué dans le milieu extérieur mais canalisé (channeling) vers le domaine ADCS. Finalement, nous avons observé que l'ADC, produit final de la réaction, retro-inhibe le domaine ADCS en absence d'ADC lyase. Pris dans son ensemble, nos résultats indiquent que l'amination du chorismate est l'étape la plus limitante de la synthèse du pABA,.. Des expériences de criblage à haut débit nous ont permis d'identifier une molécule, la rubreserine, qui inhibe in vitro le domaine GAT de l'ADC synthase d'Arabidopsis avec un Ki autour de 8 µM. Nous avons observé que cette molécule inhibe la croissance de plantules d'Arabidopsis thaliana et la prolifération des parasites Toxoplasma gondii et Plasmodium falciparum avec des IC50 respectif de 65 µM, 20 µM et 1.2 µM. Chez Arabidopsis, la concentration en folate des cellules traitées est abaissée d'environ 40% par rapport au contrôle, une diminution qui n'a plus lieu en présence de pABA. L'ajout de pABA et de 5-formyltetrahydrofolate dans les milieux de culture d'Arabidopsis ou de Toxoplasma supprime en grande partie l'inhibition de croissance liée à la rubreserine, ce qui montre bien la connexion entre rubreserine et voie de biosynthèse du folate. Avec Toxoplama gondii, la rubreserine apparait plus efficace que les sulfamides pour bloquer l'invasion et la prolifération de ces parasites dans les fibroblastes humains. Ces résultats valident la GAT-ADCS comme cible anti-folate et montrent que la rubreserine a des propriétés anti-parasitaires intéressantes. / The term folate (vitamin B9) is a family of molecules with a basic structure composed of 3 parts: a core pterin, a para amino benzoic acid (PABA) moiety and a chain of glutamate. The role of these cofactors is to carry one-carbon groups. They are involved in many reactions such as the synthesis of nucleic acids, the synthesis of methionine and the synthesis and turnover of S-adenosylmethionine. Folate is synthesized in plants and many micro-organisms including parasites of the Apicomplexa phylum such as Plasmodium falciparum and Toxoplasma gondii. Several enzymes involved in the pathway are absent in humans, and so they are potential targets for herbicide, antibiotic and antiparasitic drugs. Inhibitors of folate biosynthesis (such as dihydropteroate synthase inhibitors, or inhibitors of dihydrofolate reductase), are often used as antibiotics and pesticides. A major problem in treating these infectious diseases is the resistance developed against these molecules, which requires a constant search for new drugs. pABA is synthesized in several steps which are all attractive targets for developing new inhibitors. First the aminodeoxychorismate (ADC) synthase converts chorismate into ADC, and then, in a second step, the ADC is converted to pABA by an ADC lyase. In higher plants and apicomplexan parasites the ADC synthase is a bifunctional enzyme composed of two main domains: a glutamine amidotranferase (GAT) domain that produces NH3, and an ADC synthase domain (ADCS) that catalyzes the amination of chorismate. We determined the kinetic parameters of the Arabidopsis GAT-ADCS. We found that these two domains function independently, that is to say either in the presence of glutamine alone for the GAT domain (no chorismate) or in the presence of chorismate and NH3 for the ADCS domain (no glutamine). However, the tandem operation of the two domains (all substrates are present) improves the kinetic properties (kcat) of each one. Our results also show that the NH3 produced by the GAT domain and required for the synthesis of ADC is not released into the surroundings but rather channeled to the active site of ADCS. Finally, we observed that ADC, the final product of the reaction, retro-inhibits the ADCS domain in the absence of ADC lyase. Taken together, our results indicate that the amination reaction of chorismate is the most limiting step of the synthesis of pABA. Using high-throughput screening approaches we have identified a molecule, rubreserine, which inhibits in vitro the GAT domain of Arabidopsis GAT-ADCS with a Ki value around 8 µM. We observed that this molecule inhibits the growth of Arabidopsis thaliana seedlings and the proliferation of Toxoplasma gondii and Plasmodium falciparum parasites with respective IC50 of 65 µM, 20 µM and 1 µM. In Arabidopsis, the concentration of folate in rubreserine-treated cells is lowered by about 40% compared to controls, a decrease that is suppressed in the presence of pABA. The addition of pABA and 5-Formyltetrahydrofolate in the culture media of Arabidopsis and Toxoplasma partly reverses the growth inhibition due to rubreserine, which shows the connection between the drug and folate biosynthesis. Rubreserine appears more effective than sulfa-drugs to block the invasion and proliferation of Toxoplasma gondii in human fibroblasts. These results validate the GAT-ADCS as an anti-folate target and show that rubreserine has interesting anti-parasitic properties.